OVIT Stock UPDATES Oncovista Innovative Therapies I (OVIT) 0.2700

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Oncovista Innovative Therapies I (OVIT) 0.2700 $OVIT

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2013
M2 - Tue Sep 10, 3:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/snxwsx/acute_lymphocytic) has announced the addition of the "Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2013" report to their offering. 'Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia). Scope - A snapshot of the global therapeutic scenario for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia). - A review of the Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Johnson & Johnson Amgen Inc. Sanofi-Aventis Seattle Genetics, Inc. MedImmune LLC medac GmbH Gamida Cell Ltd. Bio-Path Holdings, Inc. Millennium Pharmaceuticals, Inc. Novartis AG Pfizer Inc. Incyte Corporation 4SC AG IMMUNOMEDICS, INC Ariad Pharmaceuticals, Inc. OncoVista Innovative Therapies, Inc. Jazz Pharmaceuticals, Inc. Portola Pharmaceuticals, Inc. Mundipharma International Limited MorphoSys AG Lipoxen PLC and many more... For more information visit http://www.researchandmarkets.com/research/sn...ymphocytic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

OTC Daily Alert Stock Watch - OncoVista Innovative Therapies, Inc. (OTCQB:OVIT)
WorldStockWire - Tue Aug 13, 6:15PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com

Colon Cancer - Pipeline Review, H2 2013 Gives Coverage of the Colon Cancer Pipeline on the Basis of Route of Administration and Molecule Type
M2 - Mon Aug 12, 12:10PM CDT
Research and Markets (http://www.researchandmarkets.com/research/kfjngz/colon_cancer) has announced the addition of the "Colon Cancer - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Colon Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Colon Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Colon Cancer. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Colon Cancer. - A review of the Colon Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - AEterna Zentaris Inc. - Advenchen Laboratories, LLC - Affichem - Alethia Biotherapeutics Inc. - AlphaVax, Inc. - Cell Therapeutics, Inc. - Curis, Inc. - Cytokinetics, Inc - DEKK-TEC, Inc. - Eli Lilly and Company - Etubics Corporation - Five Prime Therapeutics, Inc. - Geistlich Pharma AG - ISA Pharmaceuticals B.V. - Isofol Medical AB - Kalos Therapeutics, Inc. - Lorus Therapeutics Inc - MabVax Therapeutics, Inc. - Northwest Biotherapeutics, Inc. - NovaLead Pharma Pvt. Ltd. - OncoMed Pharmaceuticals, Inc. - OncoVista Innovative Therapies, Inc. - Patrys Limited - PharmaMar, S.A. - Pharminox Limited - Pique Therapeutics - Tautatis Incorporated - Telik, Inc. - Transgene Biotek Ltd - Viventia Biotechnolo For more information visit http://www.researchandmarkets.com/research/kf...lon_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Investors of Sage Therapeutics Have Chance to Join Lawsuit

Updated Category News Views 88

Introduction to the Class Action Lawsuit Attention, investors! There's an important opportunity arising for shareholder litigation against Sage Therapeutics, Inc. The legal firm Bronstein, Gewirtz & Grossman, LLC is officially notifying individuals who have invested in Sage Therapeutics about a class action lawsuit that has now been filed. If you have faced substantial...

Continue Reading
FARO Technologies Revolutionizes 3D Metrology with Leap ST

Updated Category News Views 105

FARO Technologies Enhances 3D Metrology with Leap ST FARO Technologies, Inc. (NASDAQ: FARO) is pushing the boundaries of handheld scanning technology with the introduction of the Leap ST. This launch marks a significant expansion of FARO's product portfolio, positioning the company among the few firms offering a comprehensive range of portable 3D metrology solutions. Leap...

Continue Reading
Strong Financial Performance and Growth Strategies at TORM PLC

Updated Category News Views 181

TORM PLC Reports Robust Q3 2025 Financial Results TORM PLC has demonstrated remarkable resilience and adaptability, reporting its strongest quarterly results in 2025. This achievement underscores the effectiveness of TORM's integrated operating model, as highlighted by the CEO. The company continues to prioritize creating long-term value for its shareholders while...

Continue Reading
Manhattan Associates Faces Legal Challenges Amid Shareholder Losses

Updated Category News Views 304

Manhattan Associates Faces Legal Challenges Following Shareholder Loss In recent developments, Manhattan Associates, Inc. (NASDAQ: MANH) is under scrutiny as a class action lawsuit has been filed against the company. This action comes after an alarming drop in shareholder value, amounting to over $4 billion. The lawsuit is pivotal as it involves allegations of misleading...

Continue Reading
BioLife Solutions Announces Upcoming Financial Results

Updated Category News Views 91

BioLife Solutions to Share Key Financial Insights BioLife Solutions, Inc. (NASDAQ: BLFS), a pioneering developer and supplier of bioproduction products and services specializing in cell and gene therapies, is gearing up for a significant event. The company plans to release its financial results for the third quarter of 2024 after market hours on November 12, 2024. This is...

Continue Reading